Recombinant Mouse IL-2 Protein

概述

产品介绍

Cat No. IL-2-PM2001

库存：现货

Size

点击咨询在线客服

产品介绍

纯度

> 92 % as determined by SDS-PAGE

内毒素

< 1.0 EU per μg protein as determined by the LAL method.

生物活性

1. Measured by its ability to bind recombinant human IL2Ra-Fc (Cat:10165-H02H) in a functional ELISA.
2. Measured in a cell proliferation assay using CTLL2. The ED₅₀ for this effect is typically 6-30 ng/mL.

蛋白构建

A DNA sequence encoding the soluble form of mouse IL2 (P04351) (Ala 21-Gln 169) was expressed, with an initial Met at the C-terminus.

Accession#

P04351

表达宿主

E. coli

种属

Mouse

预测 N 端

Met

分子量

The recombinant mouse IL2 consists of 150 amino acids and has a calculated molecular mass of 17.4KDa. It migrates as an approximately 19 kDa in SDS-PAGE under reducing conditions.

缓冲液

Lyophilized from sterile PBS, 2mM DTT, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

运输方式

In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

稳定性 & 储存条件

Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

复溶

To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA.

Measured in a cell proliferation assay using CTLL2. The ED₅₀ for this effect is typically 6-30 ng/mL.

Recombinant Mouse IL-2 Protein: 别称

Il-2 Protein, Mouse; Il2 Protein, Mouse

IL-2 背景信息

Interleukin-2, also known as a T-cell growth factor, TCGF, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells). Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2 and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy is ineffective.

全称

interleukin 2

研究领域

Neuroinflammation

相关通路图

Common G-Chain signaling pathway

参考文献

Smith KA, et al.,1980, J. Exp. Med.151 (6): 1551-6.
Smith KA, et al.,1980, Nature. 287 (5785): 853-5.
Taniguchi T, et al.,1983, Nature. 302 (5906): 305.
Cantrell DA, et al.,1984, Science. 224 (4655): 1312-6.
Smith KA, et al.,1988, Science. 240 (4856): 1169-76.
Wang X. et al., 2005, Science 310:1159-63.
Stauber D.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 2788-93.